Which companies overlap with Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.'s portfolio?

Top competitors by shared drug class: Taejoon Pharmaceutical Co., Ltd., Allergan, Chong Kun Dang Pharmaceutical, Oslo University Hospital, Andrew B Adams.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/zhaoke-guangzhou-ophthalmology-pharmaceutical-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. pipeline: 2 marketed, 0 filed, 6 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 6 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Hypromellose Eye Drop	Hypromellose Eye Drop	marketed	Artificial tear lubricant / Ophthalmic demulcent		Ophthalmology
Hypromellose Eye Drops	Hypromellose Eye Drops	marketed	Artificial tear / Ocular lubricant		Ophthalmology
CsA Ophthalmic Gel	CsA Ophthalmic Gel	phase 3	Calcineurin inhibitor	Calcineurin	Ophthalmology
Cyclosporine ophthalmic gel vehicle	Cyclosporine ophthalmic gel vehicle	phase 3	Calcineurin inhibitor	Calcineurin	Ophthalmology
CsA-PG Ophthalmic Gel	CsA-PG Ophthalmic Gel	phase 3	Calcineurin inhibitor	Calcineurin	Ophthalmology
Levobetaxolol eye drops	Levobetaxolol eye drops	phase 3	Selective beta-1 adrenergic antagonist (beta-blocker)	Beta-1 adrenergic receptor	Ophthalmology
Lower dose atropine sulfate eye drops	Lower dose atropine sulfate eye drops	phase 3	Muscarinic antagonist / Anticholinergic	Muscarinic acetylcholine receptors (M1, M3)	Ophthalmology
Betaxolol eye drops	Betaxolol eye drops	phase 3	Selective beta-1 adrenergic antagonist (beta-blocker)	Beta-1 adrenergic receptor	Ophthalmology

Therapeutic area mix

Ophthalmology · 9

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Taejoon Pharmaceutical Co., Ltd. · 2 shared drug classes
Allergan · 2 shared drug classes
Chong Kun Dang Pharmaceutical · 2 shared drug classes
Oslo University Hospital · 2 shared drug classes
Andrew B Adams · 1 shared drug class
Armando Torres Ramírez · 1 shared drug class
Albert Einstein Healthcare Network · 1 shared drug class
Andover Research Eye Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.:

Cite this brief

Drug Landscape (2026). Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zhaoke-guangzhou-ophthalmology-pharmaceutical-ltd. Accessed 2026-05-17.